Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Enwei Pharmaceutical CoSZSE:301331 -0.86%76 Gross Margin % is 55.69% as of Mar. 2026, which is 1% below its 10-year median of 56.34. GuruFocus rates SZSE:301331 with a GF Score™ of 76/100 and a GF Value™ of ¥28.16 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 939 Drug Manufacturers companies, Enwei Pharmaceutical Co ranks better than 54.42% on this metric.
SZSE:301331's Gross Margin % is ranked better than 54.42% of 939
companies
in the Drug Manufacturers industry
Industry Median: 48.54
vs SZSE:301331: 51.05
Enwei Pharmaceutical Co had a gross margin of 55.69% for the quarter that ended in Mar. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Enwei Pharmaceutical Co was -2.90% per year.
Enwei Pharmaceutical Co (SZSE:301331) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Enwei Pharmaceutical Co had a gross margin of 55.69% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Enwei Pharmaceutical Co Gross Margin % Related Terms
Enwei Pharmaceutical Co Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Enwei Pharmaceutical Co's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Enwei Pharmaceutical Co Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Enwei Pharmaceutical Co's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Enwei Pharmaceutical Co's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Enwei Pharmaceutical Co (SZSE:301331) has a Gross Margin % of 55.69% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Enwei Pharmaceutical Co and its competitors. This is near median its historical median of 56.34. Over the past decade, Enwei Pharmaceutical Co's Gross Margin % has ranged from 49.51 to 68.27. According to the industry distribution chart, Enwei Pharmaceutical Co ranks #428 out of 939 companies in the Drug Manufacturers industry, placing it in the top 45.6%.
Is Enwei Pharmaceutical Co's Gross Margin % too high?
Enwei Pharmaceutical Co's current Gross Margin % of 55.69% is near median its 10-year median of 56.34. Over the past 10 years, this metric has ranged from a low of 49.51 to a high of 68.27. The Drug Manufacturers industry median Gross Margin % is 48.54. Enwei Pharmaceutical Co's value of 55.69% is 14.7% above this industry median. Based on the distribution chart, Enwei Pharmaceutical Co ranks #428 out of 939 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Enwei Pharmaceutical Co has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Enwei Pharmaceutical Co's Gross Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Enwei Pharmaceutical Co ranks #428 out of 939 companies for Gross Margin %. This puts Enwei Pharmaceutical Co in the upper half of its industry. The industry median Gross Margin % is 48.54. Enwei Pharmaceutical Co's value of 55.69% is 14.7% above this benchmark. Historically, Enwei Pharmaceutical Co's own Gross Margin % has ranged from 49.51 to 68.27 over the past decade. While the company's 10-year median is 56.34 vs. the industry median of 48.54, Enwei Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.54, based on 939 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Enwei Pharmaceutical Co's current Gross Margin % of 55.69% is 14.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Enwei Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Enwei Pharmaceutical Co's current Gross Margin % is 55.69%, which is near median its own 10-year median of 56.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enwei Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Enwei Pharmaceutical Co (SZSE:301331) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥28.16, compared to a current price of ¥21.84 — trading 22.4% below its estimated fair value. The current Gross Margin % is 55.69%, which is near median its 10-year median of 56.34 and 14.7% above the Drug Manufacturers industry median of 48.54. Enwei Pharmaceutical Co's overall GF Score™ is 76/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Enwei Pharmaceutical Co (SZSE:301331), the current Gross Margin % is 55.69% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Enwei Pharmaceutical Co (SZSE:301331) Overvalued in 2026?
Based on GuruFocus' analysis, Enwei Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥21.84 is trading 22.4% below its estimated GF Value™ of ¥28.16.
GuruFocus considers Enwei Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for SZSE:301331:
Gross Margin %: 55.69% (near median its 10-year median of 56.34)
GF Value™: ¥28.16 vs. price of ¥21.84 (22.4% below fair value)
Industry Position: 14.7% above the Drug Manufacturers median (#428 of 939)
No single metric tells the full story. See the SZSE:301331 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Enwei Pharmaceutical Co Ltd is engaged in the research and development, production, and sales of proprietary Chinese medicines and chemical medicines. The company mainly procures Chinese medicinal herbs, processed Chinese medicinal herbs, chemical raw materials, excipients, packaging materials, plastics, and other miscellaneous items.
76GF Score
Get the complete analysis for SZSE:301331
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SZSE:301331 has been successfully added to your 
